Biochemistry and Biophysics Reports (Dec 2021)

GAP-43 ameliorates Podocyte injury by decreasing nuclear NFATc1 expression

  • Zhiwen Lian,
  • Guibao Ke,
  • Hong Zhang,
  • Caoshuai Dou,
  • Xueqin Chen,
  • Bohou Li,
  • Fengxia Zhang,
  • Shichun Wen,
  • Qiong Wu,
  • Yubin Xia,
  • Nan Jiang,
  • Zhuo Li,
  • Sijia Li,
  • Xingchen Zhao,
  • Jianchao Ma,
  • Ting Lin,
  • Feng Wen,
  • Lixia Xu,
  • Zhilian Li,
  • Huabang Liang,
  • Wei Dong,
  • Yuanhan Chen,
  • Ruizhao Li,
  • Zhiming Ye,
  • Wenjian Wang,
  • Xinling Liang,
  • Wei Shi,
  • Li Zhang,
  • Shuangxin Liu

Journal volume & issue
Vol. 28
p. 101145

Abstract

Read online

Podocyte injury is sufficient to cause glomerulosclerosis and proteinuria, eventually leading to kidney failure. Previous studies found that podocytes and neurons had similar biological characteristics. Growth-associated protein-43 (GAP-43) is a growth cone protein in neurons, and a marker of axonal and synaptic growth. However, it is not known whether GAP-43 is expressed in podocytes. Compared with normal glomerular podocytes, GAP-43 was significantly reduced in patients with glomerular diseases. GAP-43 also significantly reduced in lipopolysaccharide (LPS)-treated podocytes. We found that the decreased expression of nephrin, the cell marker of the podocyte, was significantly recovered with GAP-43 overexpression. In contrast, the migration ability in LPS-treated podocyte was reduction after GAP-43 overexpressing. Moreover, overexpression of GAP-43 attenuated podocyte apoptosis by up-regulating the ratio of Bcl-2/Bax with LPS treatment. Finally, Plaue and Rcan1 which are downstream target gene of NFATc1 decreased with overexpression of GAP-43 podocytes. We concluded that GAP-43 attenuated podocyte injury by inhibiting calcineurin/NFATc1 signaling. The findings may provide a promising treatment for podocyte injury-related diseases.

Keywords